<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02366013</url>
  </required_header>
  <id_info>
    <org_study_id>rcAd001/IAVI R001</org_study_id>
    <nct_id>NCT02366013</nct_id>
  </id_info>
  <brief_title>Trial of the Safety and Immunogenicity of an Oral, Replicating Ad26 Vectored HIV-1 Vaccine</brief_title>
  <official_title>A Phase 1 Clinical Trial of the Safety and Immunogenicity of an Oral, Replicating Adenovirus 26 Vector Vaccine for HIV-1 (rcAd26.MOS1.HIV-Env) in Healthy HIV-1-uninfected Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International AIDS Vaccine Initiative</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>International AIDS Vaccine Initiative</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a dose escalation study to test the safety and immunogenicity of an oral HIV-1
      vaccine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a phase I dose-escalation randomized, double blind, placebo-controlled study
      designed to evaluate the safety and immunogenicity of rcAd26.MOS1.HIV-Env, an oral
      replicating adenovirus 26 vector vaccine in healthy HIV-1 uninfected adults. The vaccine will
      be administered orally at a single time point (Day 0) at one of four dose levels depending on
      study group: 1 x 10^8 virus particles (vp), 1 x 10^9 vp, 1 x 10^10 vp and 1 x 10^11 vp.
      Volunteers will be randomized to vaccine: placebo in a 5:1 ratio in each group.

      Volunteers will be screened up to 56 days before vaccination and will be followed for 12
      months after vaccination.

      Because the vaccine is replication competent, volunteers will be housed in an isolation unit
      from day -2 through day 9. Household contacts will also be enrolled and tested for possible
      transmission.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability as measured by number of volunteers reporting the following:</measure>
    <time_frame>4 Months post-vaccination</time_frame>
    <description>Any adverse events within 4 months following vaccination (SAEs within 12 months following vaccination)
Moderate or greater unsolicited adverse events related to study product (i.e., suspected adverse reactions) within 4 weeks post-vaccination
Moderate or greater solicited reactions within 9 days post-vaccination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion (95%CI) of volunteers per dose group with positive shedding responses and mean response per group with 95% CI.</measure>
    <time_frame>28 days</time_frame>
    <description>o Rectal/oral shedding: real-time PCR for rcAd26.MOS1.HIV-Env at 1, 2, 3, 4, 5, 6, 7, 8, 9, 12, 17, 21, 7, 12, 21, and 28 days after vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of volunteers per dose group with positive immunological responses and mean response (e.g. GMT) per group with 95% CI.</measure>
    <time_frame>12 Months</time_frame>
    <description>Cellular immunogenicity: Env-specific ELISPOT responses at 4 weeks after vaccination.
Humoral immunogenicity: Env-specific binding antibody titers at 4 weeks after vaccination.
Durability of responses: immunogenicity assays at 4, 8 and 12 months after vaccination.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose of rcAd26.MOS1.HIV-Env 1x10^8 vp or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose of rcAd26.MOS1.HIV-Env 1x10^9 vp or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose of rcAd26.MOS1.HIV-Env 1x10^10 vp or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose of rcAd26.MOS1.HIV-Env 1x10^11 vp or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rcAd26.MOS1.HIV-Env 1x10^8 vp</intervention_name>
    <description>1 oral capsule, 1x10^8 vp/capsule or 1 placebo capsule; 5:1 vaccine:placebo</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rcAd26.MOS1.HIV-Env 1x10^9 vp</intervention_name>
    <description>10 oral capsules, 1x10^8 vp/capsule or 10 placebo capsules; 5:1 vaccine:placebo</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rcAd26.MOS1.HIV-Env 1x10^10 vp</intervention_name>
    <description>1 oral capsule, 1x10^10 vp/capsule or 1 placebo capsule; 5:1 vaccine:placebo</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rcAd26.MOS1.HIV-Env 1x10^11 vp</intervention_name>
    <description>10 oral capsules, 1x10^10 vp/capsule or 10 placebo capsules; 5:1 vaccine:placebo</description>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-40 years old.

          -  Ability and willingness to provide informed consent.

          -  Complete an assessment of understanding

          -  Available for the duration of the trial, including willingness to be kept in an
             isolation facility

          -  From Day 10 through 4 months following vaccination must reside alone or with no more
             than 2 adults (age 18-60) and no minors under age 18

          -  Good general health as shown by medical history, physical exam, and screening

          -  Willing to undergo HIV testing and willing to receive risk reduction counseling

          -  All female volunteers must be willing to undergo urine pregnancy tests

          -  Sexually active males must be willing to use an effective method of contraception
             until at least 4 months after vaccination

          -  Women of child bearing potential commit to use an effective method of contraception
             when sexually active with males for 4 months after vaccination

          -  Willing to forgo donations of blood or any other tissues during the study and, for
             those who test HIV positive due to trial vaccination (vaccine-induced HIV
             seroreactivity), until the anti-HIV antibody titers become undetectable

          -  Low risk for HIV infection and willing to maintain low-risk behavior for the trial
             duration

        Exclusion Criteria:

          -  Confirmed HIV-1 or HIV-2 infection; confirmed HCV, HBV, or syphilis infection

          -  Current or planned participation in another clinical trial of an experimental agent
             during the study period

          -  Pregnant or lactating

          -  Significant acute or chronic disease, including inflammatory bowel disease or other
             chronic gastrointestinal disease, immunodeficiency syndrome, or condition requiring
             immunosuppressant medications

          -  Use of anticancer, antituberculosis or other medications considered significant by the
             investigator within the previous 6 months

          -  Receipt of live-attenuated vaccine within the previous 60 days or planned receipt
             within 60 days after vaccination with Investigational Product (within 14 days for live
             attenuated influenza vaccine [LAIV]); or receipt of other vaccine (e.g., influenza,
             pneumococcal), allergy treatment with antigen injections or tuberculin skin test
             within the previous 14 days or planned receipt within 14 days after vaccination with
             Investigational Product

          -  Receipt of blood transfusion or blood-derived products within the previous 3 months

          -  Receipt of HIV vaccine(s) in a prior HIV vaccine trial.

          -  Previous severe local or systemic reactions to vaccination

          -  History of splenectomy

          -  History of seizure in the last 3 years

          -  Known autoimmune disease

          -  Asthma other than mild, well-controlled asthma.

          -  Diabetes mellitus type 1 or type 2

          -  Thyroidectomy, or thyroid disease requiring medication during the last 12 months

          -  Angioedema within the last 3 years if episodes are considered serious or have required
             medication within the last 2 years

          -  Hypertension

          -  Body mass index (BMI) â‰¥ 40

          -  Bleeding disorder diagnosed by a doctor

          -  Malignancy (Not excluded: a volunteer with a surgical excision and subsequent
             observation period that in the investigator's estimation has a reasonable assurance of
             sustained cure or is unlikely to recur during the study period)

          -  Psychiatric condition that compromises safety of the volunteer or precludes compliance
             with the protocol

          -  All healthcare workers with direct patient contact

          -  Childcare worker who has direct contact with children

          -  Individuals employed as food handlers or otherwise engaged in the preparation or
             delivery of food outside of their place of residence

          -  Positive urine toxicology test

        Household contacts 18-60 years of age are also evaluated for eligibility with a more
        abbreviated list of inclusion/exclusion criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Treanor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathryn Stephenson, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2015</study_first_submitted>
  <study_first_submitted_qc>February 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2015</study_first_posted>
  <last_update_submitted>November 18, 2016</last_update_submitted>
  <last_update_submitted_qc>November 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>HIV Prevention</keyword>
  <keyword>HIV Vaccine</keyword>
  <keyword>Healthy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

